Controls | RA | ||
---|---|---|---|
(n=246) | (n=323) | p | |
Age, years | 54 ± 16 | 55 ± 10 | 0.62 |
Female, n (%) | 162 (66) | 263 (81) | <0.001 |
BMI, kg/m2 | 30 ± 3 | 28 ± 5 | <0.001 |
Abdominal circumference, cm | 100 ± 6 | 97 ± 13 | <0.001 |
Cardiovascular data | |||
CV risk factors, n (%) | |||
Current smoker | 47 (19) | 64 (20) | 0.83 |
Obesity | 67 (27) | 104 (32) | 0.20 |
Hypertension | 92 (37) | 101 (31) | 0.13 |
Diabetes mellitus | 42 (17) | 42 (13) | 0.16 |
Blood pressure, mm Hg | |||
Systolic | 139 ± 8 | 133 ± 19 | <0.001 |
Diastolic | 84 ± 5 | 81 ± 12 | 0.001 |
Statins, n (%) | 66 (27) | 104 (32) | 0.19 |
Disease-related data | |||
CRP at time of study, mg/l | 2.0 (1.1–4.6) | 2.6 (1.3–6.1) | 0.023 |
Disease duration, years | 8 (4–15) | ||
ESR at time of study, mm/1° hour | 25 (12–45) | ||
Rheumatoid factor, n (%) | 218 (67) | ||
ACPA, n (%) | 179 (55) | ||
DAS28-ESR | 2.32 ± 1.19 | ||
DAS28-PCR | 2.54 ± 1.05 | ||
SDAI | 12 (6–20) | ||
CDAI | 8 (4–14) | ||
HAQ | 0.750 (0.250–1.250) | ||
Current drugs, n (%) | |||
Prednisone | 123 (38) | ||
Prednisone doses, mg/day | 5 (3–5) | ||
NSAIDs | 154 (48) | ||
DMARDs | 277 (86) | ||
Methotrexate | 238 (74) | ||
Leflunomide | 72 (22) | ||
Hydroxychloroquine | 37 (11) | ||
Sulfasalazine | 25 (8) | ||
Anti-TNF therapy | 68 (21) | ||
Tocilizumab | 17 (5) | ||
Rituximab | 6 (2) | ||
Abatacept | 6 (2) | ||
JAK inhibitors | 7 (2) | ||
Historical disease-related data | |||
History of extraarticular manifestations, n (%) | 24 (7) | ||
Erosions, n (%) | 113 (35) | ||
CRP at time of disease diagnosis, mg/l | 6.4 (2.5–17.1) | ||
CRP >3 at time of disease diagnosis, n (%) | 152 (47) | ||
ESR at disease diagnosis, mm/1° hour | 31 ± 19 | ||
Subclinical atherosclerosis | |||
Carotid IMT, microns | 698 ± 137 | ||
Carotid plaques, n (%) | 124 (38) |